Skip to main navigation

Close

About Us
Our Science
- Publications
Pipeline
Patients
Investors
Culture & Careers
Contact Us

COVID-19 Information
Privacy Policy
Terms of Use
Do Not Sell My Personal Information

Follow Us

About Us
Our Science
- Publications
Pipeline
Patients
Investors
Culture & Careers
Contact Us

Press Releases

Overview
Press Releases
Events and Presentations
Stock Information
- Stock Quote & Chart
- Analyst Coverage
SEC Filings
Governance
Investor Resources

Please click here if you wish to receive an e-mail notification regarding Alector press releases.

Year

May 07, 2026

Alector Reports First Quarter 2026 Financial Results and Provides Business Update

Apr 29, 2026

Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis

Feb 25, 2026

Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 24, 2026

Alector to Participate in the TD Cowen 46th Annual Health Care Conference

Be the first to hear about our latest discoveries.

About Us
Our Science
- Publications
Pipeline
Patients
Investors
Culture & Careers

Follow Us

COVID-19 Information
Privacy Policy
Terms of Use
Do Not Sell My Personal Information

Copyright Alector, Inc. 2026.

The information regarding our therapeutic candidates and the patients they are intended to treat on this site is intended only for residents of the U.S.

Close

Are you sure you want to leave?

You are about to leave the Alector site. Please note our privacy policy won’t apply to these third-party sites.

Continue

Cancel